Status:
COMPLETED
An Extension Study of TS-152 in Subjects with Rheumatoid Arthritis
Lead Sponsor:
Taisho Pharmaceutical Co., Ltd.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
To evaluate the long-term safety and efficacy of TS-152 in subjects with Rheumatoid Arthritis who have completed the previous study (TS152-3000-JA study or TS152-3001-JA study).
Eligibility Criteria
Inclusion
- At visit1(-4 weeks), Subject must be fully informed about the study and must obtain written informed consent from the subject himself.
- At Visit2(0 week), Subjects must have completed the previous study (TS152-3000-JA or TS152-3001-JA) ,and must have completed all evaluations required at the follow-up visit.
- etc.
Exclusion
- Subjects who had serious adverse drug reactions in the previous study.
- At Visit1(-4 weeks) or Visit2 (0 week), Subjects who have not recovered from clinically important adverse events.
- etc.
Key Trial Info
Start Date :
October 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2023
Estimated Enrollment :
401 Patients enrolled
Trial Details
Trial ID
NCT04077567
Start Date
October 1 2019
End Date
April 28 2023
Last Update
February 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan